Quality Control In Procurement

New USP Chapter <1110>: Microbial Contamination Control Strategy Considerations The United States Pharmacopeia (USP) has introduced a new general chapter <1110> titled "Microbial Contamination Control Strategy Considerations." This chapter provides a comprehensive framework for developing and implementing an effective contamination control strategy (CCS) throughout the entire product lifecycle, applicable to both sterile and nonsterile products. This initiative aligns with international regulatory expectations and emphasizes the integration of Quality Risk Management (QRM) principles. It encourages manufacturers to proactively identify, evaluate, and control microbiological risks by establishing a documented and science-based CCS. Key elements of Chapter <1110> include: Facility Design and Cleanroom Classification: The chapter highlights the importance of cleanroom design in accordance with ISO 14644-1 standards. ISO Class 5 conditions are required for aseptic processing areas to ensure minimal contamination. Environmental Monitoring (EM): A robust EM program should monitor both viable (microbiological) and nonviable particles. Data should be reviewed regularly (e.g., quarterly) to identify trends and adjust alert and action limits accordingly. Risk Assessment Methodologies: Tools such as Hazard Analysis and Critical Control Points (HACCP) and Failure Modes and Effects Analysis (FMEA) are recommended to identify critical control points. Risk mitigation strategies must be justified and documented. Ongoing Verification: The CCS should be reviewed periodically, incorporating existing site-specific and global microbial risk assessments to ensure continuous improvement and compliance. Why is Chapter <1110> Important? Chapter <1110> marks a significant step toward unifying standards for microbial contamination control. It promotes a proactive, lifecycle-based approach that enhances product quality and patient safety. The new guidance is also closely aligned with current global regulations, including the EU GMP Annex 1 revisions. The draft chapter was published in Pharmacopeial Forum 51(2) in March 2025, and stakeholders are invited to provide feedback during the public comment period before it is finalized.

SUPPLIER QUALITY AUDIT CHECKLIST: 1.Quality Management System 1.Verify if the supplier is certified to ISO 9001 or IATF 16949. 2.Check for the presence of a documented Quality Policy and measurable objectives. 3.Confirm that roles, responsibilities, and authorities are clearly defined. 4.Ensure quality manuals and procedures are up-to-date and controlled. 2.Incoming Material Control 1.Review procedures for inspecting incoming materials. 2.Check whether Certificates of Conformance (CoC) or test reports are verified. 3.Confirm that non-conforming incoming materials are recorded and managed appropriately. 3.Process Control 1.Verify that work instructions are available and followed at each workstation. 2.Identify whether critical processes are controlled with defined parameters. 3.Check if in-process inspection is conducted systematically. 4.Look for the use of Statistical Process Control (SPC) tools like control charts or histograms for key operations. 4.Final Inspection and Testing 1.Ensure there is a procedure for final product inspection and testing. 2.Confirm that inspection records are maintained. 3.Check if outgoing products are verified against customer requirements. 4.Verify traceability systems for finished goods. 5.Equipment Calibration and Maintenance 1.Review the calibration schedule for measuring instruments. 2.Check if all gauges and instruments are calibrated with valid certificates. 3.Ensure preventive maintenance plans are in place and followed. 6.Non-Conformance and Corrective Action 1.Examine how internal and customer-related non-conformances are handled. 2.Check if root cause analysis methods like 5Why or Fishbone diagrams are used. 3.Ensure corrective and preventive actions are tracked to closure with effectiveness verification. 7.Document and Record Control 1.Confirm that records are retained as per defined retention policies. 2.Check whether document revisions are controlled and updated systematically. 8.Supplier/Sub-supplier Management 1.Verify if sub-suppliers are evaluated periodically. 2.Ensure the supplier has defined quality expectations and requirements for their own suppliers. 9.Training and Competency 1.Check whether employees are trained and competent for their assigned tasks. 2.Ensure training records are maintained and effectiveness is evaluated. 10.Continuous Improvement 1.Look for evidence of continuous improvement initiatives such as Kaizen, 5S, or Six Sigma. 2.Check whether improvement goals are set, monitored, and reviewed regularly. 11.Environment, Health & Safety (EHS) 1.Ensure that safety measures, signage, and personal protective equipment (PPE) are available and used. 2.Verify the implementation of 5S principles in the workplace. 3.Check for compliance with environmental and legal regulations. 12.Customer Satisfaction and Support 1.Review how customer feedback and complaints are collected and analyzed. 2.Check whether timely and effective actions are taken in response to customer issues.

Risk-based contamination control strategy of manufacturing non-sterile pharmaceutical products: Identifying Equipment-Related Causes of Contamination When developing a Contamination Control Strategy for non-sterile pharmaceutical products, it's essential to start by identifying potential causes of contamination. Utilizing tools like the Ishikawa (fishbone) diagram helps structure the thought process and identify various root causes. Equipment-Related Causes of Contamination 1. Inadequate Equipment for the Process One of the primary equipment-related causes of contamination is the use of machinery that may not be suitable for the intended process. This can lead to improper containment or handling of materials, increasing the risk of contamination. To address this issue, it is imperative to ensure that equipment is selected and designed with contamination control in mind. Regular assessment of equipment's appropriateness for the processes is essential to prevent contamination. 2. Untrained Personnel for Cleaning of the Equipment Cleaning is a critical step in preventing contamination in non-sterile pharmaceutical manufacturing. Untrained personnel may not execute cleaning procedures correctly, leaving behind residues or contaminants. Comprehensive training programs should be in place to educate cleaning staff on the importance of their role and the proper techniques for effective cleaning. 3. Non-Existing Plan for Regular Checks of the Laminar Flow Laminar flow cabinets play a crucial role in maintaining a clean and controlled environment during pharmaceutical manufacturing. Without regular checks and maintenance, the laminar flow's effectiveness can degrade, allowing contaminants to enter the workspace. Implementing a preventive maintenance plan and scheduled checks can help ensure the laminar flow remains efficient. 4. Inadequate Materials of the Parts That Are in Contact with the Product Inadequate materials may react with the product or degrade over time, potentially leading to contamination. Ensuring that all materials in contact with the product are of the highest quality and compatibility is vital for contamination control. Equipment-related causes, as identified through the Ishikawa diagram, present a significant area of concern. To address these causes and minimize the risk of contamination, pharmaceutical manufacturers should focus on equipment selection, cleaning validation, personnel training, laminar flow maintenance, material compatibility, cleaning agent selection, and SOPs. By addressing these aspects comprehensively, pharmaceutical companies can enhance product quality, safety, and consumer trust. Published paper: https://lnkd.in/dtWghe7R Poster presentation October 2022: https://lnkd.in/dB3ZKCrU

𝗛𝗫-𝟮 𝗶𝗻 𝗨𝗸𝗿𝗮𝗶𝗻𝗲: 𝗪𝗵𝗲𝗻 “𝗔𝗜 𝗦𝘁𝗿𝗶𝗸𝗲 𝗗𝗿𝗼𝗻𝗲𝘀” 𝗛𝗶𝘁 𝘁𝗵𝗲 𝗕𝗮𝘁𝘁𝗹𝗲𝗳𝗶𝗲𝗹𝗱 🔍 A very modern problem just went public: battlefield feedback vs. marketing narrative. Bloomberg reported Ukraine was holding off on further HX-2 orders after frontline setbacks. Helsing responded: orders are not paused and demand is growing. ⚠️ What the “pause” story claims ▪️ Frontline trials reportedly showed takeoff/reliability issues ▪️ Some AI/autonomous features expected in the package were allegedly missing during tests ▪️ Concerns included vulnerability to electronic warfare (per unnamed sources and an internal presentation referenced in reporting) 🛡️ What Helsing claims instead ▪️ Concrete requests from more than six Ukrainian units to order HX-2 ▪️ The tested unit allegedly requested 1,000+ additional drones after “successful trials” ▪️ HX-2 approved for frontline use, listed in Ukraine’s central ordering system, with deliveries at several hundred per month 🧩 The real lesson (for every procurement team watching) ▪️ “AI” is not a feature — it’s an acceptance test. Define what autonomy must do under jamming, and verify it with instrumented trials. ▪️ Flight reliability beats fancy guidance. If launch and recovery cycles aren’t boringly repeatable, nothing downstream matters. ▪️ Narratives diverge fast in wartime. Both can be true at once: one unit has issues; other units still want the capability (or want an improved block). ▪️ Architecture matters: if you can’t upgrade software, EW hardening, and guidance in spirals, you’re buying a frozen product into a learning war. 💬 𝘐𝘧 𝘢 𝘴𝘺𝘴𝘵𝘦𝘮 𝘤𝘢𝘯’𝘵 𝘴𝘶𝘳𝘷𝘪𝘷𝘦 𝘴𝘤𝘳𝘶𝘵𝘪𝘯𝘺 𝘧𝘳𝘰𝘮 𝘧𝘳𝘰𝘯𝘵𝘭𝘪𝘯𝘦 𝘰𝘱𝘦𝘳𝘢𝘵𝘰𝘳𝘴, 𝘪𝘵 𝘸𝘢𝘴 𝘯𝘦𝘷𝘦𝘳 “𝘈𝘐-𝘦𝘯𝘢𝘣𝘭𝘦𝘥.” 𝘐𝘵 𝘸𝘢𝘴 𝘫𝘶𝘴𝘵 𝘢 𝘱𝘪𝘵𝘤𝘩. #LoiteringMunitions #DroneWarfare #ElectronicWarfare #DefenseTech #DefenseProcurement #MilitaryInnovation

𝗛𝗼𝘄 𝘀𝘁𝗿𝗼𝗻𝗴 𝗶𝘀 𝘆𝗼𝘂𝗿 𝗣𝗿𝗼𝗰𝘂𝗿𝗲𝗺𝗲𝗻𝘁 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 ��𝗲𝗳𝗲𝗻𝘀𝗲? Quality failures are a major cause for Supply Chain incidents. But they don’t happen overnight. Issues and incidents slip through gaps in systems, processes, and people, bypassing layers of risk defense. The 𝗦𝘄𝗶𝘀𝘀 𝗖𝗵𝗲𝗲𝘀𝗲 𝗠𝗼𝗱𝗲𝗹, introduced by James Reason in 1990, is a powerful way to visualize how a series of weaknesses can align, creating a “window of opportunity” for errors or harm. Problems occur when multiple layers of defense fail at the same time. In Procurement, quality and risk management require a layered approach. No single measure is enough to stop risks like supplier failures or product malfunctions. Thinking about Procurement, find here a reflection on the six dimensions of a quality defense system: 1️⃣ 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 & 𝗖𝘂𝗹𝘁𝘂𝗿𝗲 starts at the top. Leaders set the tone, embedding quality as a shared priorities for teams and suppliers alike. Without this commitment, the first layer of defense crumbles, leaving gaps for issues to pass through. 2️⃣𝗦𝘁𝗮𝗻𝗱𝗮𝗿𝗱𝗶𝘀𝗲𝗱 𝗣𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 make results predictable and reduce risks. Having a good handle on process metrics and controls mitigate possible weaknesses and entry points for issues. Weak processes are like holes in the systems, creating a pathway for failure. 3️⃣𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗿𝗶𝗴𝗵𝘁𝘀 have a clear purpose. They enable quick decision-making based on well-defined roles & responsibilities. Slow or ambiguous decision processes allow small issues to escalate into large problems. 4️⃣𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 like those built on ISO 9001 ensure issue prevention, detection and continuous monitoring. Having this layer in place reinforces consistency, accountability and governance of operations. 5️⃣𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲𝘀 & 𝗽𝗲𝗼𝗽𝗹𝗲 make quality happen. Clear roles, training, and collaboration tools empower effective actions. When everyone understands their accountability and purpose, risks are identified and resolved faster. 6️⃣𝗧𝗲𝗰𝗵 & 𝗱𝗮𝘁𝗮 provides the tracking mechanisms and insights to stay ahead. Relevant data, predictive analytics and performance metrics help teams to monitor risks and address issues before they escalate. Each of these six layers adds a critical line of defense. If one fails, the next must catch the issue before it impacts the customer. ❓How strong are your procurement defenses. ❓Where do you see gaps, and how can you strengthen your layers. #procurement #qualitymanagement #swisscheesemodel

694 grams of weight stolen from every chicken. The thief? Something you can't see. Most producers blame genetics or feed quality when growth slows. But research reveals the real culprit hiding in plain sight: ammonia in your litter.   Zhou et al. exposed broilers to just 35 ppm ammonia from day 22. The result? Birds weighed only 1,522 grams at 43 days compared to 2,216 grams in clean air. That's 694 grams lost per bird.   Here's what makes ammonia dangerous: it steals profits silently. No dramatic symptoms. Birds just grow slower. Feed conversion gets worse. You might not even smell it until levels hit 50+ ppm.   The math is brutal. When litter moisture exceeds 25%, bacterial breakdown accelerates. Poor ventilation traps gases at bird level. Your eyes watering in the barn? Ammonia already reached unsafe levels for your flock.   The solution starts with measurement.   Weight tracking reveals ammonia problems before they become obvious. When growth curves flatten, elevated ammonia should be your first suspect. Smart litter management follows: wood shavings, 20-25% moisture, proper ventilation.   Professional operations understand this connection. Environmental control and performance measurement work together. You can't optimize what you can't accurately measure.

The recent Philips Warning Letter from FDA calls out several things that are applicable to all teams, and we can learn from this helpful reminder: 1) you must maintain an approved supplier list, you must have a supplier management SOP and evidence you are following it ("Supplier Management Plans" are a great idea, with regular, documented performance and operations reviews) 2) you must assess your suppliers for adequacy and document this (audit your suppliers with auditors who understand the actual regulations those suppliers fall under and their services.... think GMP auditors auditing GCP suppliers -- there is real risk in that approach!)) 3) your metrics requirements and risk management plan must include metrics for every single thing you say you are going to measure - you should assess performance, not just simple metrics 4) your corrective actions (the "CA" in CAPA) must include HOW you will show these CAs are adequate ("Verification of Effectiveness") 5) your suppliers must have a requirement to notify you of changes in services ("Change Notification Process") in their contract with you 6) "internal suppliers" are still suppliers and fall under your ASL, supplier evaluation/audit, and Supplier Management Requirements 7) Your complaints process must include ALL aspects per 21 CFR 820.198(a) 8) You must have a complete CAPA procedure and evidence you are following it. You MUST open CAPAs when needed 9) and more https://lnkd.in/g3RQ3tTz

Pentagon Tests Portable 3D-Printing Labs to Turn Battlefields Into Drone Factories Introduction The U.S. Department of Defense is experimenting with a radical shift in military logistics: replacing long, vulnerable supply chains with portable, on-demand manufacturing. In recent tests in Hawaii, the Pentagon demonstrated mobile 3D-printing labs that allow soldiers to design, print, and assemble drones within hours, directly in the field. What the Pentagon Is Testing The initiative focuses on deployable manufacturing units designed for austere environments. • Portable 3D-printing labs that can be transported and set up rapidly • Capability for troops to design drone components locally • End-to-end production, from digital design to assembled aircraft, in hours Why Drones Are the First Target Unmanned systems are ideal for battlefield manufacturing. • Drones are relatively small and modular • They are expendable and frequently lost in combat • Rapid iteration allows designs to be adapted to mission needs and enemy tactics Strategic Motivation The effort is driven by hard lessons from recent conflicts. • Traditional supply lines are fragile and easily targeted • Replacement parts and systems can take weeks or months to arrive • On-site production reduces dependence on centralized logistics hubs Operational Implications If scaled, this approach could reshape military operations. • Units gain autonomy to replace and modify equipment in real time • Logistics footprints shrink, improving survivability • Innovation cycles move from contractors to the tactical edge Why It Matters This test signals a shift toward distributed, software-driven warfare where manufacturing is as mobile as troops themselves. By turning battlefields into micro-factories, the Pentagon is betting that speed, adaptability, and resilience will outweigh mass production. If successful, on-demand manufacturing could redefine how future wars are fought, supplied, and sustained. I share daily insights with 35,000+ followers across defense, tech, and policy. If this topic resonates, I invite you to connect and continue the conversation. Keith King https://lnkd.in/gHPvUttw

Risk assessment is a vital part of pharmaceutical quality systems to ensure product safety and regulatory compliance. ICH Q9: Quality Risk Management Main Guideline for implementing risk assessment and control processes in pharmaceuticals. Focuses on: Risk identification Risk analysis Risk evaluation Risk control Risk review Quality Risk Assessment and Mitigation Plan covering critical areas like labeling, filtration, and packing processes. Each failure mode is assessed for severity, occurrence, and detectability (S, O, D) to determine the Risk Priority Number (RPN). Based on this, mitigation strategies are implemented to control or reduce risk. Row 57: Labeling Container for Individual Identification Failure Mode: Wrong label pasted on ampoules/vials. Effect: High chance of missing product information — serious issue, can lead to market complaints and misidentification. Cause: Wrong product label from store department. Current Controls: Label details are recorded in batch packing record. Verified by production and QA. Labels are checked during issuance as per BPR. RPN: 4 (Low category risk). Post Risk: Adequate control; no recommendation needed. Row 58: Labeling of Container for Dispatch Failure Mode: Wrong product details on packed carton. Effect: Risk of missing correct product info — leads to market complaints. Cause: Wrong product detail impression on carton. Current Controls: Carton is checked by QA. Verification against stereo impression log and BMR. Destroyed stereo and mix-up checks included. RPN: 4 (Low category risk). Post Risk: No additional action required. Row 59: Packing Through Blister Machine Failure Mode: Missing batch coding on blister foil. Effect: Missing product info — leads to complaint. Cause: Roller defect during blistering. Current Controls: Each set of foil is verified by QA. In-process QA and production checks. RPN: 4 Post Risk: No change needed. Row 60: Packing Through Hi-Cart Failure Mode: Missing batch coding on inner carton. Effect: Market complaint due to missing info. Cause: Stereo impression error. Controls: Production + QA verify batch coding. In-process logbook and destroyed stereo monitoring. RPN: 4 Post Risk: Control adequate. Row 61: Packing Process Failure Mode: Packed products get mixed. Effect: Wrong product distribution. Cause: Improper segregation between products. Controls: Segregation followed after every product batch. RPN: 4 Post Risk: No extra action required. Each of these failure modes is associated with a low RPN, indicating controls are effective, and no additional risk mitigation is currently necessary.

One bad supplier can destroy years of good work.   Most MedTech companies learn this the hard way.   Your suppliers aren't just vendors. They're extensions of your quality system.   When they fail, you fail. When patients suffer, you're responsible.   Here's how to build supplier quality that protects everyone:   Start with Smart Qualification ↳ Verify their ISO 13485 status ↳ Check FDA compliance history ↳ Audit before you approve ↳ Assess financial stability   Build Strong Agreements ↳ Define clear quality expectations ↳ Set measurable KPIs ↳ Require change notifications ↳ Secure audit rights   Monitor Continuously ↳ Use risk-based audit schedules ↳ Track delivery and defect rates ↳ Hold regular review meetings ↳ Update risk classifications   Control When Needed ↳ Enforce CAPA for issues ↳ Review performance scorecards ↳ Escalate persistent problems ↳ Document all decisions   Drive Improvement Together ↳ Share learnings from complaints ↳ Work on joint improvements ↳ Train on new requirements ↳ Recognize top performers   The truth about supplier quality?   It's not about policing. It's about partnership.   Your best suppliers want to succeed with you. Give them the tools and clarity they need.   Remember:   Good supplier management prevents problems. Great supplier management drives innovation.   Which matters more in MedTech? Both. Always both. Because every component matters. Every supplier counts. Every decision impacts patient safety. Get this right, and compliance becomes collaboration. ⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡⬡ MedTech regulatory challenges can be complex, but smart strategies, cutting-edge tools, and expert insights can make all the difference. I'm Tibor, passionate about leveraging AI to transform how regulatory processes are automated and managed. Let's connect and collaborate to streamline regulatory work for everyone! #automation #regulatoryaffairs #medicaldevices